|
For
all periods presented in this report, convertible notes, stock options, and warrants were not included in the computation of diluted
net loss per share because such inclusion would have had an antidilutive effect.
| |
|
Three
months ended |
|
| |
|
March
31, |
|
| |
|
2017 |
|
|
2016 |
|
| Excluded potentially
dilutive securities (1): |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| Convertible
note - principal |
|
|
702,247 |
|
|
|
- |
|
| Consulting warrants
to purchase common stock |
|
|
12,500 |
|
|
|
491,364 |
|
| Options to purchase
common stock |
|
|
892,129 |
|
|
|
767,074 |
|
| Financing
and IPO warrants to purchase common stock |
|
|
2,384,464 |
|
|
|
975,380 |
|
| Total
potential dilutive securities |
|
|
3,991,340 |
|
|
|
2,233,818 |
|
| |
(1) |
The
number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as
of the period end. Such amounts have not been adjusted for the treasury stock method or weighted average outstanding calculations
as required if the securities were dilutive. |
|